|
|
|
| Evaluation of the Regulatory Effect and Safety of Immune Checkpoint Inhibitors Combined with Interventional Therapy on Tumor Metabolic Activity in Elderly Patients with Advanced Non-small Cell Lung Cancer |
| Liu Liang, Yang Qin, Lai Yong |
| Meishan Second People's Hospital(Renshou County People's Hospital),Meishan,Sichuan 620500 |
|
|
|
|
Abstract Objective To investigate the regulatory effect of immune checkpoint inhibitors combined with interventional therapy on tumor metabolic activity in elderly patients with advanced non-small cell lung cancer and to evaluate its safety. Methods A total of 100 elderly patients diagnosed with advanced non-small cell lung cancer and admitted to the Second Department of Oncology of Meishan Second People's Hospital from January 2023 to April 2025 were enrolled as research subjects.Among them,80 cases underwent bronchial artery embolization and 20 cases received ablation therapy.All patients were treated with interventional therapy combined with immune checkpoint inhibitors.Clinical efficacy,quality of life,survival rates,and adverse reactions were compared between the two groups. Results The 6-month and 1-year survival rates in the bronchial artery embolization group were 90.00% and 80.00%,respectively,while those in the ablation group were both 100.00%.Tumor metabolic activity-related parameters in both groups decreased significantly after treatment compared with baseline(P<0.05).Adverse reactions in the entire cohort were predominantly mild(grade 1~2).Hematological toxicity occurred in 21 cases(21.00%),including 4 cases of grade 3 severe hematological toxicity;gastrointestinal reactions in 23 cases(23.00%);thyroid dysfunction in 20 cases(20.00%);liver dysfunction in 17 cases(17.00%);fatigue in 12 cases(12.00%);and rash in 8 cases(8.00%).No grade 4~5 severe or fatal adverse reactions were observed throughout the study. Conclusion The combination of interventional therapy and immune checkpoint inhibitors can significantly improve clinical efficacy,prolong survival,effectively suppress tumor metabolic activity,and exhibit manageable adverse reactions in elderly patients with advanced non-small cell lung cancer,demonstrating high clinical promotion value.
|
|
Received: 20 April 2026
|
|
|
|
|
|
[1] 周婵,张小乔,张丽莎,等.无化疗放射治疗联合免疫检查点抑制剂治疗局部晚期非小细胞肺癌的研究进展[J].中国医药导报,2024,21(21):68-70.
[2] 唐浩淳,孟珺,夏铮铮,等.免疫检查点抑制剂治疗晚期非小细胞肺癌安全性的回顾性研究[J].今日药学,2025,35(6):457-462.
[3] 洪乔军,韩冬冬,方瑜,等.免疫检查点抑制剂联合安罗替尼治疗晚期非小细胞肺癌的临床疗效[J].临床药物治疗杂志,2024,22(8):63-68.
[4] 张诒田. 参麦注射液联合化疗药物、免疫检查点抑制剂对老年晚期驱动基因阴性非小细胞肺癌治疗的影响[J].当代医药论丛,2024,22(19):128-131.
[5] 丁利回,岳红梅,白雪.免疫检查点抑制剂联合化学疗法在老年晚期非小细胞肺癌治疗中的应用进展[J].山东医药,2024,64(3):96-100.
[6] 刘荣,宁厚法,崔新江.支气管动脉化疗栓塞联合替雷利珠单抗治疗局部晚期非小细胞肺癌临床效果分析[J].介入放射学杂志,2025,34(5):477-481.
[7] 涂欢. 靶向治疗联合介入治疗对晚期非小细胞肺癌分析[J].保健文汇,2025,26(8):25-28.
[8] 李昱瑾,李赛囡.支气管动脉化疗栓塞介入联合免疫治疗中晚期非小细胞肺癌患者的临床研究[J].青海医药杂志,2025,55(8):1-6.
[9] 张翠翠,刘敏.微波消融联合常规化疗方案治疗晚期非鳞状非小细胞肺癌的临床效果[J].临床医学研究与实践,2025,10(27):68-71.
[10] 李琛,向世强.基于炎症指标和营养指标构建微波消融联合免疫治疗的晚期非小细胞肺癌患者预后列线图模型[J].数理医药学杂志,2024,37(12):899-911. |
| [1] |
Li Hongjie, Li Peng, Ma Yulian, Xie Zhijiang, Li Qin, Guo Junhua, Li Zhimei, Song Wei. Predictive Value of Serum BDNF,Ghrelin and MPO Levels in Patients with Coronary Heart Disease after PCI[J]. journal1, 2026, 46(5): 1-5. |
| [2] |
Ren Yuan Yuan. Distribution Characteristics of Pathogens and Risk Factors of Ventilator-Associated Pneumonia in Patients with Acute Exacerbation of COPD[J]. journal1, 2025, 45(1): 11-13. |
| [3] |
. [J]. journal1, 2024, 44(3): 84-86. |
| [4] |
. [J]. journal1, 2024, 44(1): 125-127. |
| [5] |
. [J]. journal1, 2023, 43(5): 55-57. |
| [6] |
. [J]. journal1, 2023, 43(2): 47-49. |
|
|
|
|
2026, Vol. 46 
